Concomitant administration of targeted drugs such as PI3K-ß inhibitor, bcl-2 family apoptosis inhibitor ABT-737 or histone deacetylase inhibitors such as LBH589 was evinced to regulate tumor apoptosis and enhance the sensitivity of resistant cancer cells in preclinical studies [100,101,102]. This evidence concerns the gene BCL2 and cancer.